Galderma Research & Development Snc

Metabasis Therapeutics, Inc.

Semicon Bio

Structural Bioinformatics Inc.

Roswell Biotechnologies, Inc.

Darryl Rideout

Magnus Pfahl

Ruth F Nutt

Barry L Merriman

Joseph Edward Semple

Paul Mola

Xian-Ping Lu

Hongyue Zhang

Zacharia S Cheruvallath

Tim Geiser

Jing Wang

Venkatachalapathi Yalamoori

Hengyi Zhu

Kalyanaraman Ramnarayan

Jason J Sun

Colin J Loweth

Feiyue Wu

Shankari Mylvaganam

Jianzhong Sun

Mark Shenderovich

Jian Hua Zheng

Christina Niemeyer

In various embodiments, synthetic bridge molecules are disclosed, usable in molecular electronics sensors. In various aspects, bridge molecules comprise fused ring polycyclic aromatic hydrocarbon structures in the shape of a long and narrow ribbon, with end groups on opposite short ends for selective binding to metal electrodes, one or more substituents near the midpoint of a long edge for binding to a probe molecule, and one or more additional substituent groups for solubility or other effects. In various embodiments, the bridge molecules herein are conducting, and provide a closed circuit in a sensor when forming a bridge between gapped electrodes.

Polycyclic aromatic bridges for molecular electronic sensors

Compounds and compositions are provided for modulating the activity of protein tyrosine phosphatases. In one embodiment, the compounds and compositions are thiazoles and thiadiazoles that inhibit the activity of protein tyrosine phosphatase 1B.

Thiazole and thiadiazole inhibitors of tyrosine phosphatases

The invention relates to the discovery that specific adamantyl or adamantyl group derivatives containing retinoid-related compounds induce apoptosis of cancer cells and therefore may be used for the treatment of cancer, including advanced cancer. Also, the present invention relates to novel adamantyl or adamantyl group derivatives containing retinoid compounds and their usage for treatment and/or prevention of cancer, keratinization disorders, dermatological conditions, and other therapies More specifically, it has been shown that such adamantyl compounds, e.g., 6-&lsqb;3-(1-adamantyl)-4-methoxyphenyl&rsqb;-2-naphthoicacid, 2-&lsqb;3-(1-adamantyl)-4-methoxyphenyl&rsqb;-5-benzimidazole carboxylic acid, and 6-&lsqb;3-(1-adamantyl)-4,5-methylenedioxyphenyl&rsqb;-2-naphthoic acid, can be used to treat or prevent cervical cancers and precancers such as cervical dysplasias, including high grade and low grade dysplasias.

Apoptosis inducing adamantyl derivatives and their usage as anti-cancer agents, especially for cervical cancers and dysplasias

The invention relates to the discovery that specific adamantyl or adamantyl group derivatives containing retinoid-related compounds induce apoptosis of cancer cells and therefore may be used for the treatment of cancer, including advanced cancer. Also, the present invention relates to novel adamantyl or adamantyl group derivatives containing retinoid compounds and their usage for treatment and/or prevention of cancer, keratinization disorders, dermatological conditions, and other therapies More specifically, it has been shown that such adamantyl compounds, e.g., 6-&lsqb;3-(1-adamantyl)-4-methoxyphenyl&rsqb;-2-naphthoic acid, 2-&lsqb;3-(1-adamantyl)-4-methoxyphenyl&rsqb;-5-benzimidazole carboxylic acid, and 6-&lsqb;3-(1-adamantyl)-4,5-methylenedioxyphenyl&rsqb;-2-naphthoic acid, can be used to treat or prevent cervical cancers and precancers such as cervical dysplasias, including high grade and low grade dysplasias.

Methods and compositions that act as specific inhibitors of ALF activity for the prophylaxis and treatment of anthrax infections.

Inhibitors of anthrax lethal factor activity

Apoptosis inducing adamantyl derivatives and their usage as anti-cancer

Growing community of inventors

San Diego, CA, United States of America

Darryl Rideout